November 2004

The race to commercialize MRAM has entered the home stretch.Who’s going to come in first, who’s going to profit, and how is it all going to affect the landscape of nanotech investment? We remain confident of NVE’s prospects despite some vocal detractors of NVEC, and a few investment firms are beginning to wake up to this potential.

Read more here 

Although integration of the technology is not complete, Micromem is now at a stage to enable the company's acting CTO, Dr. Cynthia Kuper and CFO Dan Amadori to address cost modeling. This step will allow the company to begin the process of identifying a manufacturing and/or development partner.